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The introduction of advanced therapy medicinal products (ATMPs) to the global pharma
market has been revolutionizing the pharmaceutical industry and has opened new
routes for treating various types of cancers and incurable diseases. In the past two
decades, a noticeable part of clinical practices has been devoting progressively to these
products. The first step to develop such an ATMP product is to be familiar with other
approved products to obtain a general view about this industry trend. The present
paper depicts an overall perspective of approved ATMPs in different countries, while
reflecting the degree of their success in a clinical point of view and highlighting their
main safety issues and also related market size as a whole. In this regard, published
articles regarding safety, efficacy, and market size of approved ATMPs were reviewed
using the search engines PubMed, Scopus, and Google Scholar. For some products
which the related papers were not available, data on the relevant company website were
referenced. In this descriptive study, we have introduced and classified approved cell,
gene, and tissue engineering-based products by different regulatory agencies, along
with their characteristics, manufacturer, indication, approval date, related regulatory
agency, dosage, product description, price and published data about their safety and
efficacy. In addition, to gain insights about the commercial situation of each product, we
have gathered accessible sale reports and market size information that pertain to some
of these products.
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INTRODUCTION
Based on Directive 2001/83/EC, medicinal products in Europe
have been defined as any substance or combination of substances
that have the capability to treat or prevent diseases in humans
or may be used with the purpose to restore, correct, or modify
physiological functions in conjunction with the capability to
be used for medical diagnosis in humans. With the advent of
new gene and/or cell therapies and in order to assure their
Abbreviations: 6MWT, 6-minute walk test; AALS, Appel ALS; AAV, adeno-
associated virus; ABPI, ankle brachial pressure index; ACKFBC, Allogeneic
Cultured Keratinocytes and Fibroblasts in Bovine Collagen; ADA-SCID, adenosine
deaminase severe combined immunodeficiency; ADC, adipose tissue-derived cell;
ADL, activities of daily living; AL, allogeneic; ALS, amyotrophic lateral sclerosis;
ALSFRS, Amyotrophic Lateral Sclerosis Functional Rating Scale; AMDDC,
autologous monocyte-derived mature dendritic cell; AMI, acute myocardial
infarction; ASD, atrial septal defect; AT, autologous; ATMP, advanced therapy
medicinal product; AT-MSC, adipose tissue-derived mesenchymal stem cell; AVN,
avascular necrosis; AVR, aortic valve reconstruction; B-ALL, B-cell precursor
acute lymphoblastic leukemia; BCVA, best-corrected visual acuity; BM-MSC, bone
marrow-derived mesenchymal stem cell; CAGR, compound annual growth rate;
CAR, chimeric antigen receptor; CD, Crohn’s disease; CEA, cultured epidermal
autograft; CFDA, China Food and Drug Administration; CLI, critical limb
ischemia; COBLT, cord blood transplantation; CR, complete remission; CRT,
cardiac resynchronization therapy; CTLA4Ig, cytotoxic T-lymphocyte associated
protein 4 immunoglobulin; DB, dermal burn; DC, dendritic cell; DCGI, Drug
Controller General of India; DDB, deep dermal burn; DFS, disease-free survival;
DFU, diabetic foot ulcer; DLBCL, diffuse large B-cell lymphoma; DRR, durable
response rate; DTH, delayed type hypersensitivity; EFS, event-free survival; EMA,
European Medicines Agency; FDA, Food and Drug Administration; FST, full-
field light sensitivity testing; FVC, forced vital capacity; GACI, gel-type autologous
chondrocyte implantation; GM-CSF, granulocyte macrophage colony stimulating
factor; GTMP, Gene Therapy Medicinal Product; GvHD, graft-versus-host disease;
HAS, Heath Administration of Singapore; HCEpC, human corneal epithelial
cell; HDFn, human dermal fibroblasts, neonatal; HEKn, human epidermal
keratinocytes, neonatal; HPC, hematopoietic progenitor cell; HNSCC, head and
neck squamous cell carcinoma; hRPE65, human retinal pigment epithelium
65 kDa; HSCT, hematopoietic stem cell transplantation; HSV, herpes simplex
virus; ICRS, International Cartilage Repair Society; IFN-γ, interferon gamma;
IKDC, International Knee Documentation Committee; irRC, immune-related
response criteria; KLH, keyhole limpet hemocyanin; KOOS, knee injury and
osteoarthritis outcome score; KSS, Knee Society Scoring system; LCC, living
cellular construct; LPLD, lipoprotein lipase deficiency; LVEDV, left ventricular
end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, end-systolic
volume; LVRR, left ventricular reverse remodeling; mCRPC, metastatic castration-
resistant prostate cancer; MFDS, Ministry of Food and Drug Safety; MLMT,
multi-luminance mobility test; MOCART, Magnetic Resonance Observation of
Cartilage Repair Tissue; MOH, Ministry of Health; mPP, modified per protocol;
MSC, mesenchymal stem cell; MSS, MRI Scoring of Severity; NGFR, nerve growth
factor receptor; NLF, nasolabilal fold; NRM, non-relapse mortality; NSCLC, non-
small cell lung carcinoma; OA, osteoarthritis; OCD, osteochondritis dissecans;
OR, overall response; ORR, objective response rate; ORR, overall response rate;
ORR, overall remission rate; OS, overall survival; PAD, peripheral artery disease;
PAP, prostatic acid phosphatase; PBMNC, peripheral-blood mononuclear cell;
Pca, prostate cancer; PCI, percutaneous coronary intervention; PFU, plaque
forming unit; PMBCL, primary mediastinal large B-cell lymphoma; PMDA,
Pharmaceuticals and Medical Devices Agency; PR, partial remission; PRP, platelet-
rich plasma; PWD, pain-free walking distance; QOL, quality of life; r/r, relapsed or
refractory; RECIST, Response Evaluation Criteria in Solid Tumor; RFS, recurrence
free survival; RFS, relapse-free survival; SCTMP, somatic cell therapy medicinal
product; SDCS, skeletal myoblast-derived cell sheet; SOC, standard of care; SPECT,
single-photon emission computed tomography; SRA, sports and recreational
activity; TBSA, total body surface area; TEAEs, treatment emergent adverse events;
TEP, tissue engineered product; TGA, Therapeutic Goods Administration; TL-
pulsed DC, tumor lysate-pulsed dendritic cell; TNC, total nucleated cell; TREC,
T-cell receptor excision circle; TTF, time to treatment failure; TTP, time to
progression; UCCBB, University of Colorado Cord Blood Bank; SMA, spinal
muscular atrophy; SMN, survival motor neuron; VAS, visual analog scale; VEGF,
vascular endothelial growth factor; VG, vector genome; VLU, venous leg ulcer; VP,
viral particle; VSD, ventricular septal defect; Xn, xenogeneic.
appropriate quality, safety, and efficacy, these therapies were
introduced into the European medicinal product legislation in
June 2003 as a new class of medicinal products, which were later
called ATMPs. In 2007, Regulation (EC) No. 1394/2007, a specific
regulation for ATMPs, was established by the EU Commission.
This regulation divides ATMPs into four distinct types: GTMPs,
SCTMPs, TEPs, and the combined ATMPs (cATMPs). GTMPs
are products directly related to therapeutic, prophylactic, or
diagnostic effects with a recombinant nucleic acid sequence.
SCTMPs are products that contain substantially manipulated
cells or tissues, or the cells or tissues not intended to be used
for the same essential function(s) in the recipient and the donor.
TEPs are engineered cells or tissues that have the properties
of regenerating, repairing, or replacing human tissue, all in
accordance with the medicinal products general definition and
finally cATMPs comprise another type of these products and
contain one or several medical devices that are an integral part
of the GTMPs, SCTMPs, or TEPs (Hanna et al., 2016a; Detela
and Lodge, 2019). Also, each regulatory authority may provide
a certain type of definition for ATMPs. For example, in US
according to FDA, advanced therapies are regulated as biologic
products, similar to EU classification. Biological products consist
of allergenic products that includes allergen extracts, allergen
patch tests, and antigen skin tests, blood and blood products,
vaccines, xenotrasplants, and ATMPs which constitutes two sub-
categories: CGTs (Integra, 2019). “Cellular immunotherapies,
cancer vaccines, and other types of both autologous and
allogeneic cells for certain therapeutic indications, including
hematopoietic stem cells and adult and embryonic stem cells that
have been subject to substantial ex vivo manipulation constitute
cellular therapy based products, while modifying the expression
of a gene or changing the biological properties of living
cells for therapeutic use compose human gene therapy based
products” (Genzyme, 2019). Moreover, “combination products
include products that are comprised of two or more regulated
components, i.e., drug/device, biologic/device, drug/biologic, or
drug/device/biologic.” The MFDS in South Korea also define
the cell therapy product as “a medicinal product manufactured
through physical, chemical, and/or biological manipulation, such
as in vitro culture of autologous, allogeneic, or xenogeneic
cells. However, this definition does not apply to a case where
a medical doctor performs minimal manipulation (e.g., simple
separation, washing, freezing, thawing, and other manipulations,
while maintaining biological properties) that does not cause
safety problems of the cells in the course of surgical operation
or treatment at a medical center.” And a gene therapy product
is defined as “a genetic material or a medicinal product
containing such genetic material intended to be administered
to human beings for treatment of disease (Choi et al.,
2015). The regulatory guidelines regarding the (pre)submission,
details of approval procedures, marketing authorization etc.
have described thoroughly elsewhere (Detela and Lodge,
2019; EU, 2020; Luria et al., 2020). The need to establish
effective therapeutic approaches to treat incurable diseases,
notably, inherited genetic conditions, blood related disorders,
malignancies, neurodegenerative diseases, tissue regeneration,
and provide a bridge for patients awaiting organ transplantation
has encouraged the increased use of ATMPs in medical
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sciences. Interestingly, a significant growth in the research
and development phase along with the clinical use of ATMPs
has been observed in recent years. In this regard, based on
the results of three clinical trials databases: ClinicalTrials.gov,
the International Clinical Trials Registry Platform (ICTRP) of
the World Health Organization (WHO), and EudraCT, 939
clinical trials of ATMPs conducted between 1999 and June
2015 (Hanna et al., 2016b). This would indicate an increase
in investment by big pharma sponsors for ATMPs (Ten Ham
et al., 2018). Of note, potential challenges that exist in terms of
the development of ATMPs include the specific requirements
for high-technology equipment, difficulty with manufacturing
processes, complicated trial design, establishment of robust
assays for validation of identity and functionality, achieving
an expected high efficacy, avoidance of probable long-term
adverse events, regulatory considerations in terms of regulatory
cost burden and timelines etc., and, in particular, financial
issues that provide situations where the product cannot be
sold at a sufficiently high price to establish a commercially
viable product (Mount et al., 2015; Elsanhoury et al., 2017; Lee,
2018). ATMPs are based on a diverse set of most advanced
technologies (Elsanhoury et al., 2017), therefore, there is an
increased need for the technical/academic personnel involved
directly and professionally in ATMP development (Lee, 2018).
Besides, regarding the rare nature of the diseases that ATMPs
are mostly developed for, there are concerns in relation with trial
design such as the low number of patients, insufficient knowledge
respecting the disease pathogenesis and some issues with the
interpretation of endpoints for new indications (Lee, 2018). Also,
the statistical analysis of safety and efficacy is affected by the
limited number of participants (Viganò et al., 2018). On the
other hand, validating these products particularly with regard to
identity, purity, and potency is of great importance. The restricted
accessible appropriate standards and reference material along
with an inadequacy in certain guidelines are the other challenges
in this regard (McConaghie, 2017).
Financial issues may be one of the main challenges that
can negatively influence the company and consumers. A well-
known example, Glybera, is a gene therapy based drug for a
rare familial LPLD (European Medicines Agency, 2020b). Its
marketing authorization expired on October 28, 2017 following a
decision by the marketing authorization holder to not apply for a
renewal. The drug was proven to be a commercial failure because
a single dose treatment cost over one million euro per patient,
in addition to the low market size due to the fact that LPLD is a
ultra-rare disease (Senior, 2017; Cuende et al., 2018).
Cuende et al. (2018) previously described cell therapy
products with market authorization (Food and Drug
Administration, 2019a), in this extensive review thanks to
available information in the regulatory agencies and related
company’s web resources, articles, and other data sources,
we in-depth dissected and classified cell, gene, and tissue
engineering products (Tables 1–3). Data are presented in
detailed tables that has been categorized in terms of product’s
definition, manufacturer, indication, approval date and related
regulatory agency, product dosage and description, price, and
related references. In addition, based on clinical trials data, we
have further discussed each ATMP’s safety and efficacy points,
categorized by the common indication within each group. Also
included is a definition of the available market sizes and sale
reports for the related products in an attempt to clarify the
commercial point of view for each of the GTMPs, SCTMPs,
and TEPs fields.
To achieving this end, published articles regarding the
characteristics, safety and efficacy, and market size of approved
ATMPs were reviewed using the search engines PubMed, Scopus,
and Google Scholar. For some products which the related papers
were not available, data on the relevant company website was
used as reference. The type of documents used to obtain the
data were original articles, review articles, HTML documents,
and official websites of each product manufacturer. Search terms
included MeSH (Medical Subject Headings) terms, “ATMP”
“CTMP” “GTMP” “TEP” and also “product name” in addition
to each terms of “efficacy” “safety” “adverse events” “price” and
“market size.” The cut-off date for the data search was May 2020.
Collectively, this paper aims to provide a comprehensive
insight for development of other cell therapy products
for stakeholders, sponsors, manufacturing companies,




To the best of our knowledge, worldwide, there are 64 approved
ATMPs by taking into consideration that Prochymal, a CTMP
product, approved by both the FDA and Health Canada, and
the GTMP product, Kymriah, is being approved by the FDA,
EMA, and Health Canada. In addition, the FDA and EMA
both approved another GTMP product, Yescarta. Obviously,
the CTMP group, with 34 products, is the largest class. The
TEP and GTMP groups, with 20 and 10 products, follow in
order. Figure 1 shows that United States, by authorizing 23
ATMPs (11 CTMPs, 7 TEPs, and 5 GTMPs), is the pioneer
country in this field followed by South Korea with 15 ATMPs
(13 CTMPs and 2 TEPs). Figure 2 shows the indications of each
of the ATMP categories, which emphasizes the importance of
the indications related to hematologic along with skin and soft
tissue disorders (Figure 2A), skin and soft tissue related disorders
(Figure 2B), and oncology (Figure 2C) in the CTMPs, TEPs, and
GTMPs, respectively. It can be concluded that most CTMPs and
GTMPs have an autologous source (Figure 2A,C), while TEPs
involve 45 percent of allogeneic and 40 percent of autologous
products (Figure 2B).
SAFETY AND EFFICACY OF ADVANCED
THERAPY MEDICINAL PRODUCTS
(ATMPs)
Cell Therapy Medicinal Products
(CTMPs)
CTMPs can be divided into eight distinct groups with respect to
the indication for which they have been developed: hematologic



















TABLE 1 | List of approved cell therapy medicinal products (CTMPs).
No. Trade name/proper
name





1 Hemacord (Food and Drug
Administration, 2019g)
HPC, cord blood
New York Blood Center,
Inc. (United States)
HSCT US FDA 2011
November
A minimum of 5 × 108 total
nucleated cells with at least
1.25 × 106 viable













HSCT US FDA 2012 May A minimum dose of






3 Ducord HPC, cord blood
(Food and Drug
Administration, 2019e)
Duke University School of
Medicine (United States)
HSCT US FDA 2012
October
A minimum dose of
2.5 × 107 nucleated
cells/kg at cryopreservation
Bag Human cord blood-
derived HPCs
AL
4 Allocord HPC, cord blood






HSCT US FDA 2013 May A minimum of 5 × 108 TNC
with at least 1.25 × 106
viable CD34 + cells at
cryopreservation
Bag Human cord blood-
derived HPCs
AL





HSCT US FDA 2013 June 2.5 × 107 nucleated
cells/kg
Bag Human cord blood-
derived HPCs
AL
6 HPC, cord blood (Food and
Drug Administration,
2019c)
Bloodworks (United States) HSCT US FDA 2016
January
Minimum dose of 2.5 × 107
nucleated cells/kg at
cryopreservation Each bag:
5 × 108 TNC with a
minimum of 1.25 × 106
CD34 + cells in 25 ml
Bag Human cord blood-
derived HPCs
AL
7 Celevecord HPC, cord




HSCT US FDA 2016
September
A minimum dose of
2.5 × 107 nucleated
cells/kg at cryopreservation
Bag Human cord blood-
derived HPCs
AL
8 HPC, cord blood (Food and
Drug Administration,
2019b)
MD Anderson Cord Blood
Bank (United States)
HSCT US FDA 2018 June 2.5 × 107 nucleated
cells/kg
Bag Human cord blood-
derived HPCs
AL





Moderate to severe NLF
wrinkles
US FDA 2011 June ∼18 × 106 autologous
fibroblasts in 1.2 ml
suspension/three treatment
sessions spaced at
intervals of 3 to 6 weeks













































TABLE 1 | Continued
No. Trade name/proper
name















US FDA 2010 April Minimum of 50 million
activated CD54 + cells,










(Rattue, 2012; Mills, 2019)
Mesoblast, Ltd.,
International (Australia)
Acute and refractory GvHD US FDA 2015 June Intravenous administration:
Low (2 million cells/kg) High
(8 million cells/kg)









TiGenix (United States) and
Takeda (United Kingdom)
Complex perianal fistulas in
CD






AL ∼ $47,485 per
treatment





Deep 2nd degree burn
(> 30% of the TBSA) and













14 Queencell (Anterogen Co.,
2020; Ministry of Food and
Drug Safety, 2020)





≥1.0 × 106/vial (1 mL). Cell
volume: according to size






15 CureSkin (Sang-jun, 2010;
Biomedic, 2019;
S-Biomedics Ltd., 2019b)
S. Biomedics (South Korea) Depressed acne scars South Korea MFDS
2010 May

















Deep 2nd degree burns South Korea MFDS
2015 October
One syringe (2.0 × 107
skin-derived
keratinocytes/1.5 ml) to the










AL ∼ $628 per 1.5-ml




Nasojugal groove South Korea MFDS
2017 December
2 × 107 fibroblasts cells
per packaging unit; single
intradermal administration
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No. Trade name/proper
name










Focal knee cartilage defect South Korea MFDS
2001 January











Bone defects South Korea MFDS
2009 August
1 to 6 vials containing > 12
million cultured osteoblasts
per vial (0.4 ml)
Vial Human osteoblasts AT NA
20 Cartistem (Cade Hildreth,
2018; Medipost, 2019;
SCT, 2019)




500 µL/cm2 depending on











21 CreaVax-RCC (Woo, 2007;










8 doses (4 times, once
every 2 weeks); each vial:
5.0 × 107 dendritic cells in
2 ml
Vial Human DCs AT ∼ $27,000 (eight
treatments)
22 Immuncell-LC (Sun-kyu,
2016; Ministry of Food and
Drug Safety, 2019b)






Each administration: 200 ml
over a spot that contains
1.0 × 109 ∼ 2.0 × 1010
activated T-cells (16 doses)
Bag Human activated T
lymphocytes
AT >$4,500 per dose
23 Cupistem (Cade Hildreth,
2018; Anterogen Co.,
2019; Ministry of Food and
Drug Safety, 2019c)
Anterogen (South Korea) Crohn’s fistula South Korea MFDS
2012 January
Fistula diameter: (a) ≤ 1 cm
(3.0 × 107 AT-MSCs in
1 ml) (b) 1 < X < 2 cm











AMI South Korea MFDS
2011 July
(a) Under
60 kg = 10 mL/5.0 × 107
BM-MSCs (b) 61 ∼
80 kg = 14 mL/7.0 × 107
BM-MSCs c. Over





Human BM- MSCs AT $15,000 for one
shot
25 Neuronata-R (Han-soo,
2018; Corestem Inc., 2019)
Corestem (South Korea) ALS (Lou Gehrig’s Disease) South Korea MFDS
2014 July
(0.1 ml/kg) 1.0 × 106
BM-MSCs in 4 ml
self-cerebrospinal fluid




Human BM-MSCs AT ∼$55,000 annually
(24 treatments)




Knee/ankle cartilage loss India DCGI 2017
April
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No. Trade name/proper
name










Early-stage AVN of hip India DCGI 2017
April
1.2 × 107 autologous bone
cells/0.4 ml
Vial Human osteoblasts AT $1,988 per
treatment
28 Apceden AMDDC (Apac
Biotech, 2019; Safer, 2019)




6 doses (4–5 million mature







Research Pvt Ltd., 2019)
Stempeutics Research
(India)





Intramuscular injection of 1
or 2 million cells/kg body
weight










2–5 million cells suspended











Acute and refractory GvHD Japan PMDA 2015
September
Intravenous infusion of 2
million cells/kg (each bag
contains 72 million cells in
18 ml of saline) 4 ml per
minute twice weekly at an
interval of 3 days or more
for 4 weeks
Bag Human BM-MSCs AL $7,600 per bag
32 RenuDermcell (CellTech,
2019)
Cell Tech Pharmed (Iran) Facial wrinkles and acne




Intradermal injection of a








Cell Tech Pharmed (Iran) OA and knee joint arthritis Iran FDA 2018
January
A minimum intra-articular
injection of 2.0 × 107
cells/knee, totally 4.0 × 107
cells for both knees
Vial BM-MSCs AT NA
34 RecolorCell (CellTech,
2019)






cells/cm2 area of vitiligo
patches; This product is
effective for vitiligo





ADC, adipose tissue-derived cell; AL, allogeneic; ALS, amyotrophic lateral sclerosis; AMDDC, autologous monocyte-derived mature dendritic cell; AMI, acute myocardial infarction; AT, autologous; AT-MSCs, adipose
tissue-derived mesenchymal stem cell; AVN, avascular necrosis; BM-MSC, bone marrow-derived mesenchymal stem cell; CD, Crohn’s disease; CLI, critical limb ischemia; DC, dendritic cell; DCGI, Drug Controller
General of India; DFU, diabetic foot ulcer; EMA, European Medicines Agency; FDA, Food and Drug Administration; GM-CSF, granulocyte macrophage colony stimulating factor; GvHD, graft-versus-host disease;
HCEpC, human corneal epithelial cell; HPC, hematopoietic progenitor cell; HSCT, hematopoietic stem cell transplantation; ICRS, International Cartilage Repair Society; MFDS, Ministry of Food and Drug Safety; MSC,
mesenchymal stem cell; NA, not available; NLF, nasolabial fold NSCLC, non-small cell lung carcinoma; OA, osteoarthritis; OCD, osteochondritis dissecans; PAP, prostatic acid phosphatase; Pca, prostate cancer;
PBMNC, peripheral-blood mononuclear cell; PMDA, Pharmaceuticals and Medical Devices Agency; TBSA, total body surface area; TGA, Therapeutic Goods Administration; TNC, total nucleated cell; UCCBB, University
of Colorado Cord Blood Bank.










































TABLE 2 | List of approved gene therapy medicinal products (GTMPs).
No. Trade name/proper
name
Manufacturer Indications Approved by/date Dosage Product
form
Description AT/ AL Price
1 Kymriah Tisagenlecleucel





Refractory B-ALL or in
second or later relapse for





of 0.2–5.0 × 106 cells/kg
for ≤ 50 kg, and
0.1–2.5 × 108 cells/kg
for > 50 kg B-cell ALL
patients up to 25 years of
age and 0.6–6.0 × 108














Adult patients with r/r large
B-cell lymphoma after two



















AveXis (United States) Pediatric patients < 2 years
of age with SMA and
bi-allelic mutations in the
SMN1 gene













Patients up to 25 years of
age with refractory B-ALL,
who are in relapse
post-transplantation or in
second or later relapse,
and adult patients with r/r
DLBCL after two or more
lines of systemic therapy
EMA 2018 August Intravenous administration
of 0.2–5.0 × 106 cells/kg
for ≤ 50 kg, and
0.1–2.5 × 108 cells/kg
for > 50 kg B-cell ALL
patients up to 25 years of
age and 0.6–6.0 × 108












Adult patients with r/r
DLBCL and PMBCL after 2
or more lines of systemic
therapy















































TABLE 2 | Continued
No. Trade name/proper
name
Manufacturer Indications Approved by/date Dosage Product
form




laherparepvec) | FDA, 2020]







An initial dose of up to
4 × 106 PFU/ml, followed
by subsequent doses of up










7 Zalmoxis (Zalmoxis, 2016;
MolMed, 2019)















8 Strimvelis (Mullin, 2019;
Stem Cell Research, 2019)
GlaxoSmithKline (GSK,
United Kingdom)
ADA-SCID EMA 2016 May The recommended dose
range is between 2 and 20
million CD34 + cells/kg
Bag Transduced



















1.5 × 1011 AAV vector
genomes in a total volume






- $425,000 per eye
EMA 2018
September
10 Gendicine (Rosen, 2012;
Sibiono, 2019)
Shenzhen SiBiono Gene







1–4 × 1012 VP once every






- Up to $100,000 per
dose




Nasopharyngeal carcinoma CFDA 2005
November


















































TABLE 2 | Continued
No. Trade name/proper
name
Manufacturer Indications Approved by/date Dosage Product
form





3–25 year old patients with
refractory B-ALL, relapsed
after allogeneic SCT or
ineligible for SCT, or with
second or later relapse,
and adult patients with r/r
large B-cell lymphoma after
two or more lines of
systemic therapy including
DLBCL not otherwise







of 0.2–5.0 × 106 cells/kg
for ≤50 kg, and
0.1–2.5 × 108 cells/kg
for > 50 kg B-cell ALL
patients up to 25 years of
age and 0.6–6.0 × 108











Human Stem Cells Institute
(Russia)
PAD, including CLI caused
by atherosclerosis
MOH of the Russia
Federation 2011
December
2 sequential injections (i.e.,
2 vials) of 1.2 mg of pCMV-











Patients up to 12 years old
with beta thalassemia who
require regular blood
transfusions
EMA 2019 May 1.2–20 × 106 cells/mL
dispersion for infusion





AAV, adeno-associated virus; ADA-SCID, adenosine deaminase severe combined immunoeficiency; AL, allogeneic; AT, autologous; B-ALL, B-cell precursor acute lymphoblastic leukemia; CAR, chimeric antigen
receptor; CFDA, China Food and Drug Administration; CLI, critical limb ischemia; DLBCL, diffuse large B-cell lymphoma; EMA, European Medicines Agency; FDA, Food and Drug Administration; GM-CSF, granulocyte
macrophage colony-stimulating factor; HNSCC, head and neck squamous cell carcinoma; hRPE65, human retinal pigment epithelium 65 kDa; HSCT, hematopoietic stem cell transplantation; HSV, herpes simplex virus;
NA, not available; MOH, Ministry of Health; NGFR, nerve growth factor receptor; PAD, peripheral artery disease; PFU, plaque forming unit; PMBCL, primary mediastinal large B-cell lymphoma; r/r, relapsed or refractory;
SMA, spinal muscular atrophy; SMN, survival motor neuron; VEGF, vascular endothelial growth factor; VG, vector genome; VP, viral particle.










































TABLE 3 | List of approved tissue-engineered products (TEPs).
No. Trade name/proper
name
Manufacturer Indications Approvedby/date Dosage Product
form




Novartis AG (United States)
Chronic VLU, DFU US FDA 2000 June Circular disk with a
diameter and thickness of
75 and 0.75 mm in size
Bag Bi-layer
bioengineered skin










DFU > 6 weeks extended
through the dermis without
tendon, muscle, joint
capsule, or bone exposure
US FDA 2001
September















Depends on the size and
condition of the wound
Gel PRP hematogel AL $430 per treatment









50 cm2 sheets with a










AT $6,000 to $10,000
per 1% TBSA










Sheets with a diameter and
thickness of 75 and
0.75 mm, respectively,













DFU US FDA 2016
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an inner layer of
bovine collagen
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thin silicone
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79,000–316,000 cells/cm2 Sheet HCEpC containing
stem cells





CO.DON AG (Germany) Symptomatic articular
cartilage defects of the
femoral condyle and the
patella of the knee with
defect sizes up to 10 cm2
in adults




AT ∼ $12224 per
treatment
























contains > 2 × 107 cells
backed by vaseline gauze.
The amount is determined
considering the size and
condition of the wound.
Sheet Cultured
keratinocytes sheet
AL $26.5 per 1 cm2 for
products with
56 cm2 units
12 CardioCel Pure collagen




Admedus (Singapore) ASD and VSD Australia HAS 2014
November
Sheets with three sizes of
4 × 4, 5 × 8, and
14 × 7 cm2
Sheet Tissue engineered
bovine pericardium
Xn $421.13 per sheet
13 JACE Epidermis-derived








DDB + DB ≥ 30%
Japan PMDA 2007
October






8 × 10 inch sheet
14 JACC AT Chondrocyte
(Japan Tissue Engineering
Co Ltd., 2020)
J-TEC (Japan) Cartilage defect




The quantity of mixture
determined by the size of
the cartilage defect: defect
area x 0.3 ml (final cell












2019; Pricing of Approved
Cell Therapy, 2019)






3 × 108 cells)
Sheet Skeletal myoblast
sheet
AT A kit: $56000 B kit:
$15000 (Each
treatment 1 A kit
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16 Artificial transfected pigskin




Burns and other traumatic
wounds





17 Bilayer artificial skin (Cheng
et al., 2016)
Shaanxi Eyre skin Biological
Engineering (China)
Deep 2nd degree burn
wound, not more than 3rd
degree burn wound 20 cm2
(diameter <5 cm)













SinaCell (Iran) Corneal ulcer, full-thickness
DFU > 6 weeks extended
through the dermis without
tendon, muscle, joint
capsule, or bone exposure
Iran FDA 2017
March











DFU > 6 weeks extended
through the dermis without
tendon, muscle, joint
capsule, or bone exposure
Iran FDA 2017
March
One piece of 2 × 2, 3 × 3,
5 × 5, 5 × 10, or
10 × 10 cm2 implanted





















ACKFBC, allogeneic cultured keratinocytes and fibroblasts in bovine collagen; AL, allogeneic; ASD, atrial septal defect; AT, autologous; CFDA, China Food and Drug Administration; CTLA4Ig, cytotoxic T-lymphocyte
associated protein 4 immunoglobulin; DDB, deep dermal burn; DB, dermal burn; DFU, diabetic foot ulcer; EMA, European Medicines Agency; FDA, Food and Drug Administration; HAS, Heath Administration of
Singapore; HDFn, human dermal fibroblasts (neonatal); HEKn, human epidermal keratinocytes (neonatal); MFDS, Ministry of Food and Drug Safety; NA, not available; PMDA, Pharmaceuticals and Medical Devices
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FIGURE 1 | Number of authorized ATMPs worldwide, according to country. Each country has been determined by specific color, and based on the number of
authorized ATMPs. United States, South Korea, and the European Union have the highest number of approved ATMPs.
disorders, skin and soft tissue related issues, orthopedic diseases,
oncology, and immunological, cardiovascular, neurological, and
ocular related disorders.
For hematologic disorders, Hemacord (US FDA.2011),
Ducord (US FDA.2012), Allocord (US FDA.2013), Clevecord (US
FDA.2016), and four other HPC based products are approved
for hematopoietic stem cell transplantations. Each product
related efficacy has been compared against two studies: the
COBLT study and another study with retrospective information
from docket and public data (RxList, 2018; Food and Drug
Administration, 2019b,c,d,e,f,g,h) with regards to neutrophil
recovery at day 42, platelet recovery at day 100 (20,000/µL and
50,000/µL), and erythrocyte recovery at day 100. After receiving
a TNC dose of ≥ 2.5 × 107/kg HPC, from multiple cord
blood banks, the estimated values were as follows: neutrophils
(76%), platelets (20,000/µL [57%] and 50,000/µL [46%]), and
erythrocyte (65%) recovery in the COBLT study. The docket
and public data information show an estimated neutrophil
recovery of 77% and platelet recovery (50,000/µL) of 45%. On
the other hand, the three parameters for neutrophil recovery
and platelet recovery (20,000/µL and 50,000/µL) parameters
were 88, 87, and 79% for Allocord; 96, 92, and 83% for
Clevecord; 95, 92, and 71% for Ducord; 79, 62, and 55%
for HPCs Cord Blood from Clinimmune Labs; 88.2, 73.6,
and 43% for HPCs Cord Blood from MD Anderson Cord
Blood Bank; 91, 95, and, 95% for HPCs Cord Blood from
LifeSouth; and 82, 66, and 50% for HPCs Cord Blood from
Bloodworks, respectively. In addition, the reported data related
to the Hemacord study were 83% (neutrophil) and 77%
platelet (20,000/µL) recovery. The median time for neutrophil
recovery, platelet recovery (20,000/µL and 50,000/µL), and
erythrocyte recovery were 27, 90, 113, and 64 days in the
COBLT study, respectively. The median time for neutrophil
recovery and platelet recovery (50,000/µL) were 25 and 122 days
according to docket and public data information. The median
time of neutrophil recovery and platelet recovery (20,000/µL
and 50,000/µL) were 21, 48, and 56 days for Allocord; 18,
41, and 43 days for Clevecord; 21, 46, and 61 days for
Ducord; 25, 55, and 49 days for HPCs Cord Blood from
Clinimmune labs; 19, 47, and 65 days for HPCs Cord Blood
from MD Anderson Cord Blood Bank; 22, 44, and 70 days
from HPCs Cord Blood from LifeSouth; and 21.5, 46, and
53 days for HPCs Cord Blood from Bloodworks, respectively.
Also, 20 days for neutrophil recovery and 45 days for platelet
recovery (20,000/µL) were reported for Hemacord. The most
important adverse events related to the safety of these products
included hypersensitivity reactions, infusion reactions, graft-
versus-host disease, engraftment syndrome and graft failure,
malignancies of donor origin, transmission of serious infections,
and transmission of rare genetic diseases.
For skin and soft tissue related disorders, CureSkin
(South Korea MFDS.2010), Queencell (South Korea
MFDS.2010), Azficel-T (US FDA.2011), Rosmir (South Korea
MFDS.2017), and RenudermCell (Iran FDA.2018) are approved
to treat acne scars and facial wrinkles, KeraHeal (South Korea
MFDS.2006) and KeraHeal-allo (South Korea MFDS.2015) are
approved for skin burns and finally RecolorCell (Iran FDA.2019)
is indicated for different types of Vitiligo. The effectiveness of
Azficel-T was demonstrated in two studies consist of 421 total
patients at 3 and 6 months follow up. The self- and physician-
reported assessments indicated 57 and 33% improvements in the
first study, and 45 and 19% in the second study for patients who
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FIGURE 2 | The percent of approved cell, gene, and tissue engineering products, along with their related indications and product type (autologous or allogeneic).
(A) The CTMPs with 34 members constitute the largest class of ATMPs. Most of these products have an autologous source. Hematologic disorders, along with skin
and soft tissue related disorders and orthopedic disorders constitute the main fields. (B) The TEPs, with 20 products, represent the next largest class of ATMPs. The
most emphasized indications in this class are skin and soft tissue related disorders, orthopedic disorders, and cardiovascular diseases, respectively, and the
percentage of allogeneic products are more than autologous products. (C) GTMPs with 10 products comprise the last class. The first common indications are
oncology, hematologic disorders, and cardiovascular diseases, respectively. Similar to CTMPs, GTMP members mostly have autologous sources.
received Azficel-T. A two-point improvement in NLF wrinkles
was reported after 6 months. The most common adverse events
were injection-site redness, bruising, swelling, pain, hemorrhage,
edema, nodules, papules, irritation, dermatitis, and pruritus
(S-Biomedics Ltd., 2019a). Qualitative data regarding the efficacy
of CureSkin shows its superior effect in the healing process
of depressed acne scars (S-Biomedics Ltd., 2012). Moreover,
according to the product’s brochure, the most common reported
adverse events after repeated administration of CureSkin was
erythema at the injection site. Common adverse events for
Rosmir included eye irritation and allergic rhinitis (Yim et al.,
2011; Tego Science, 2019a). Regarding KeraHeal efficacy, the
take rate of 1:4–6 meshed autografts along with KeraHeal in 29
patients with burn injuries was estimated to be 96 and 100%
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at 2 and 4 weeks after treatment, respectively. A reduction in
Vancouver burn scar scale at 8, 12, and 24 weeks following
the treatment was observed (Yoon et al., 2017). The primary
outcome used to show the KeraHeal-allo efficacy was the
period of re-epithelialization, which occurred 2.5 or 2.8 days
faster in the treated sites in comparison with the control. No
associated adverse events were reported with these two products
(Park et al., 2017).
For orthopedic disorders, Cartistem (South Korea
MFDS.2012) and MesestroCell (Iran FDA.2018) are approved
for knee osteoarthritis; Chondron (South Korea MFDS.2001),
Cartigrow (India DCGI.2017), and Chondrocytes-T-Ortho-
ACI (Australia TGA.2017) are approved for defective knee
cartilage. Ossron (South Korea MFDS.2009) and Ossgrow (India
DCGI.2017) are approved for repair of bone defects. The safety
and efficacy of Cartistem was assessed in a phase I/II clinical
trial with 7 years long−term follow−up in seven patients with
osteoarthritis of the knee joint with Kellgren−Lawrence (K−L)
grade 3 and painful full−thickness cartilage defects. Results have
shown repaired tissue at 12-weeks post-transplantation, while
arthroscopic examination and biopsy at 1 year showed stable
regenerated cartilage. Furthermore, the 100-mm VAS score for
pain and the IKDC subjective score were improved at 24 weeks
post-transplantation and maintained for up to 7 years. A high
glycosaminoglycan content in the regenerated cartilage at 3 years
was determined through the mean relative change in R1 (1R1)
index. Mild to moderate adverse events included arthralgia, back
pain, and bladder distension. No particular adverse reactions
were noted over 7 years of clinical follow-up (Choi et al., 2010).
Following the Chondron transplantation in 98 patients with
articular cartilage injury of the knee joint and 13∼25-month
follow-up, assessments showed a notable improvement in
the Knee Society Scoring system (tKSS)-A (pain) and tKSS-B
(function) scores. A total of 2.04% of the patients experienced
adverse events related to GACI due to ‘catching symptom’
(Bauer et al., 2012). The safety, tolerability, and efficacy of
Chondrocytes-T-Ortho-ACI are reported from clinical trials of
1077 reported cases that showed significant improvements in the
KOOS subscales and in the 6MWT during 36 months of post-
surgery follow up in comparison with the pre-operative group.
MRI analysis also showed significant post-operative progression;
however, this observation was not sustained until the study
end point. The most common adverse events encountered
during these clinical trials included engraft failure, cartilage
hypertrophy, incomplete drug effect, and graft delamination
(Kim et al., 2009). Safety and efficacy of Ossron and Ossgrow
have been assessed in a clinical trial of 64 patients with long-bone
shaft fractures during 2 months. The average callus formation
score was significantly higher in the experimental group at
1 and 2 months of follow up, while the osteoblast injection
response was not statistically different between younger and
older patients. No adverse effects were observed in association
with the osteoblast injection (Kim et al., 2007).
In oncology, CreaVax-RCC (South Korea MFDS.2007) is
approved for metastatic renal cell carcinoma, Immuncell-
LC (South Korea MFDS.2007) is approved for post-surgical
recurrence of hepatocellular carcinoma, Sipuleucel-T (Provenge)
(US FDA.2010/EMA.2010) is approved for mCRPC, and finally,
Apceden (India DCGI.2017) is approved for Prostate, ovarian,
colorectal, and NSCLC. The safety and efficacy of CreaVax-RCC
was assessed in nine patients suffering from metastatic renal
cell carcinoma with a median follow-up of 17.5 months. This
treatment had the ability to prompt an immune response against
the tumor. Out of nine patients, one experienced a PR and a
decrease in the size of lung metastases; five had stable disease;
and three had evidence of progressive disease after one cycle of
immunotherapy. The results of the DTH skin test with KLH or
TL-pulsed DCs determined that three patients with no initial
DTH reactivity and three patients with a positive initial DTH
response to KLH- or TL-pulsed DC had positive reactions to both
after immunotherapy and experienced raised skin reactions after
the vaccination. In addition, there was an elevation in the number
of tumor specific interferon gamma (IFN-γ)-producing cells after
one cycle of the vaccination. No severe adverse effects have been
reported (Lee et al., 2015). In the Immuncell-LC phase III clinical
trial, 230 patients with HCC were assigned randomly to receive
immunotherapy 16 times during 60 weeks or no adjuvant therapy
(controls). RFS and RFS rates were considered to be the primary
outcomes. Overall survival (OS), cancer-specific survival, the
OS rate, and cancer-specific survival rate criteria accounted for
secondary outcomes. The RFS time for the immunotherapy
group was 44 months in comparison with 30 months in the
control group. The RFS rate for both groups declined during
12, 24, 36, and 48 months post-treatment; however, the amount
of statistically significant rates per month were higher in the
immunotherapy group. Both the OS rate and cancer-specific
survival rate decreased in the immunotherapy and control groups
during 12, 24, 36, and 48 months. Again, the amounts of the
statistical rates per month were higher in the treatment group.
Serious adverse events were reported in the immunotherapy
group and included hemorrhage from esophageal varices, hepatic
vein stenosis, herpes zoster, laceration, meniscus lesion, humerus
fracture, foot fracture, bladder neoplasm, and high frequency
ablation (Kantoff et al., 2010). In a phase III clinical trial, 341
patients with mCRPC received Stempeucel-T (Provenge). There
was a relative decline of 22% in the risk of death observed
in the sipuleucel-T group compared with the placebo group.
This reduction resulted in a 4.1-month improvement in median
patient survival. The most common adverse events were chills,
fever, and headache. These adverse events were more frequent
in the sipuleucel-T group than in the placebo group (Bapsy
et al., 2014). Safety and efficacy of Apceden was assessed in
a multicenter phase II clinical trial in India that enrolled 51
patients with refractory solid cancers. A significant improvement
regarding QOL and overall median survival in patients with
objective response was observed. The TTP analysis showed a
notable delay in the onset of disease development. There was an
increase in the mean CD4:CD8 ratio in the immune response
evaluation, along with an ORR of 28.9 and 42.1% by RECIST
and irRC, respectively. One adverse event, an episode of rigors
together with mild fever during a single infusion was reported
(Prasad et al., 2011).
Immunological disorders have four approved products.
Prochymal (Health Canada.2012, US FDA.2015) together with
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Temcell HS (Japan PMDA.2015) are produced to treat GvHD.
Cupistem (South Korea MFDS.2012) and Alofisel (EMA.2018)
are two other products in this group. First one is indicated
for reducing the inflammation in Crohn’s Fistula and the latter
is indicated for treatment of complex perianal fistulas in adult
patients with non-active/mildly active luminal Crohn’s disease.
In one trial, Prochymal was used to treat refractory grades III
and IV acute GvHD in 12 children. The results indicated that
allogeneic HSCT was well-tolerated. The survival rate was 42%
after a median follow up of 611 days. The OS for patients
who achieved CR was estimated to be 68% at 2 years (Muroi
et al., 2016). Temcell HS was evaluated in a phase I/II study
of 25 patients with steroid-refractory grade III or IV acute
GvHD. A statistically significant consistent CR for grade III
or IV steroid-refractory acute GvHD was shown from 4 to
52 weeks of follow up. At 52 weeks, 48% of the patients
who achieved CR were still alive. In addition, the survival of
patients who had an OR, which is the sum of the CR and PR,
was substantially higher than those with no OR. Responses in
children were better than adults. The most common adverse
events were leukocytopenia, thrombocytopenia, anemia, sepsis,
hypertension, microangiopathy, liver dysfunction, and chronic
GvHD (European Medicines Agency, 2020a).
The assessment efficacy and safety of Alofisel compared to
placebo was considered in a pivotal Phase III clinical trial. In
this study 212 perianal fistulising CD patients (107 receiving
Alofisel Cx601 and 105 receiving placebo) was screened over
24, 52, and 104 weeks. Full analysis of the efficacy data showed
combined remission of perianal fistulising CD and absence of
collections > 2 cm of the treated fistula confirmed by MRI
images, at week 24. The combined remission in the active
group was 49.5% (53/107) and in the placebo group were
34.5% (36/105). Presented data from week 52 showed statistically
significant effects in favor of Alofisel treatment, and finally in
patients who entered the 104 weeks follow-up (25 Alofisel, 15
placebo), the rate of clinical remission was 56 and 40% in the
active and placebo group, respectively (Cho et al., 2015). In a
phase II clinical trial fistula healing was evaluated 24 months
after the administration of Cupistem in 43 patients. Cupistem
seemed to be efficient considering the results of the mPP
analysis 24 months after transplantation where 80.8% of the
patients showed complete fistula healing. In order to assess the
sustainability of the initial response, complete closure in 83.3% of
the 24 patients who had evidence of complete closure at the 8th
week after the injection still had complete closure at year 2. The
most common adverse reactions were abdominal pain, eczema
and exacerbation of crohn’s disease, anal inflammation, diarrhea,
and fever. None of the observed adverse events were considered
to be related to the product (Kim et al., 2018).
Cardiovascular diseases are the next category in the field of
CTMPs. Cellgram-AMI (South Korea MFDS.2011) for AMI and
Stempeucel (India DCGI.2016) for CLI due to thromboangiitis
obliterans (Buerger’s disease) are in this group. In a clinical
study, for evaluating the safety and efficacy of Cellgram-AMI,
26 patients with successful PCI for acute ST-segment elevation
anterior wall myocardial infarction were assigned to either a
control group (n = 12) or Cellgram group (n = 14) and
were follow-up for 4-month. Patients who received Cellgram-
AMI had improved Left ventricular function as shown by a
substantial progress in overall LVEF, measured by SPECT and
echocardiography 3 months after the BM-MSC injection and
4 months after PCI. This improvement continued to the 12th
month follow up as assessed by echocardiography. However,
the baseline and 4-month LVEDV and LVESV values did not
significantly change. No adverse events, in-stent restenosis, or
proarrhythmic effects were noted in both groups during the 4
and 12-month follow up periods (Gupta et al., 2017). A phase
II study in India assessed the safety and efficacy of Stempeucel.
This study placed 90 patients with CLI due to Buerger’s disease
into two dose groups. The rest pain and ulcer size per month
were the primary outcomes. Both decreased in comparison with
the SOC group. The secondary outcomes of ABPI, amount of
total walking distance, and QOL activity score of units per month
increased for both doses. Skin ulcer and gangrene in the 1 × 106
and 2× 106cells/kg groups, respectively, were the most frequently
reported TEAEs. They were considered either remotely related or
unrelated to Stempeucel (Oh et al., 2015).
The only related neurological disorder was ALS for which
the product Neuronata-R (South Korea MFDS.2014) has been
approved. In a phase I clinical trial to evaluate the safety of
of Neuronata-R, seven patients with definite or probable ALS
received two intrathecal injections of Neuronata-R and were
follow-up for 12 months. The ALSFRS score, AALS score, and
FVC were used to assess treatment efficacy. It was shown that
none of the mentioned parameters declined rapidly and that
the decrease in ALSFRS-R score during the 6 months follow
up was more gradual than the observed decrease in the lead-
in period, while these scores remained persistent for 6 months
after the first injection of MSCs. None of the patients experienced
serious adverse events during the 12-month follow-up period
(Zhang et al., 2018).
Gene Therapy Medicinal Products
(GTMPs)
The GTMPs have been developed for oncology, hematologic,
cardiovascular, neurodegenerative, and ocular diseases.
In oncology related indications, Gendicine (CFDA.2003)
is the first approved gene therapy product to treat head and
neck squamous cell carcinoma, Imlygic (US FDA/EMA.2015)
is approved for melanoma treatment, and Kymriah (US
FDA.2017-EMA/Health Canada.2018) and Yescarta (US
FDA.2017-EMA.2018) are two products used for hematologic
malignancies. To evaluate the safety and efficacy of Gendicine,
there are over 30 clinical study related publications. This product
was assessed in a large number of clinical studies that included
more than 30,000 patients. The results showed remarkable safety
records along with improvements in efficacy, including tumor
shrinkage and an enhanced QOL. The average response rate for
CR and PR reached 90%. After the 5-year follow up, a large group
of patients were still alive. The most common adverse events
include fever, arthralgia, and myalgia (Andtbacka et al., 2015).
In a phase III clinical trial, an intralesional injection of Imlygic
was compared with subcutaneous administration of GM-CSF in
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patients with advanced melanoma. The mean treatment duration
was 23 in the Imlygic group and 10 weeks in the GM-CSF
group. The median OS was determined to be 23.3 in the patients
treated with Imlygic compared with 18.9 months in patients who
received GM-CSF. The DRR and ORR were considerably higher
in the Imlygic arm. Additional efficacy criteria included the
median TTF and median time to response which were 8.2 and
4.1 months in Imlygic treated group versus 2.9 and 3.7 months
in the GM-CSF arm. The most common reported adverse events
were fatigue, chills, and pyrexia (Maude et al., 2018). In a phase
II clinical trial, 75 pediatric and young adults with relapsed
or refractory B-ALL received Kymriah. The ORR was 81% at
3 months of follow-up. EFS and OS rates were calculated 73 and
90% at 6 months, and 50 and 76% at 12 months, respectively. The
median duration of remission and EFS were not reached, while
the rate for RFS was 80 and 59% at 6 and 12 months, respectively,
among patients who responded to treatment. The most common
non-hematological adverse reaction in 77% of patients was
cytokine release syndrome. Also, neurologic events occurred in
40% of patients (Schuster et al., 2019). In another phase II clinical
trial, to evaluate the efficacy of Kymriah therapy, 93 patients
with relapsed or refractory DLBCL were infused with Kymriah
and the median follow up time was 14 months. The best OR
was 52%, 40% of the patients had complete responses and 12%
had partial responses in a median of 2 months. After 12 months
of the initial response, the rate of RFS was estimated to be 65%
(79% among patients with a complete response). Also, cytokine
release syndrome (58%), anemia (48%), and pyrexia (35%) were
the most common adverse events of any grade (Neelapu et al.,
2017). In a phase II clinical trial, Yescarta was administrated
to 101 patients with DLBCL and PMBCL. The ORR and the
complete response rate were 82 and 54%, respectively. The OS
rates at 6, 12, and 18 months were 78, 59, and 52%. CAR T cell
levels in the blood peaked within 14 days and were detectable in
most patients at 180 days after the Yescarta infusion. The most
serious adverse reactions included cytokine release syndrome
and neurologic events (Cicalese et al., 2016).
For hematologic disorders, Strimvelis (EMA.2016) is
developed to treat adenosine deaminase deficiency derived
severe combined immunodeficiency (ADA-SCID) and Zynteglo
(EMA.2019) is approved to treat Patients up to 12 years old with
beta thalassemia who require regular blood transfusions.
In a phase II clinical trial, 18 patients with ADA-SCID received
Strimvelis. The OS in a median follow-up of 6.9 years was
100% and there were increased numbers of CD3 +, CD4 +,
CD8 + T cells, and CD16 + CD56 + NK cells as an outcome
of immune reconstitution. A slower increase in CD19 + B-
cells was reported. The TREC and lymphocyte ADA enzyme
activity both increased in peripheral blood lymphocytes after
treatment. Venous red blood cell deoxyadenosine nucleotide
levels were <100 nmol/ml. The most frequent adverse events
were respiratory and gastrointestinal tract infections (Karponi
and Zogas, 2019). Five completed and ongoing clinical trials
are existed regarding Zynteglo, HGB-205, HGB-204, HGB-207,
HGB-212, and LTF-303. During HGB-204 and HGB-205 clinical
trials, it was revealed that 11 of 18 and all of 4 enrolled patients
with transfusion-dependent beta (β)-thalassemia (TDT) in each
study met the primary endpoint which was the elimination of
RBC transfusion requirement, respectively. HGB-207, HGB-212
clinical trials and a long-term follow-up study named LTF-303
constitute the ongoing clinical trials. So far, 17 of 20 and 6
of 11 enrolled patients in HGB-207, HGB-212 clinical trials
have shown transfusion independency, respectively (European
Medicines Agency, 2020e). Thrombocytopenia constituted the
only serious adverse reaction related to Zynteglo. Moreover,
there were common adverse reactions attributed to Zynteglo
containing leukopenia, neutropenia, hot flush, dyspnea, pain in
extremity, non-cardiac chest pain, and one very common adverse
reaction as abdominal pain (ClinicalTrials, 2020).
Some of the common side effects reported in patients
receiving ZyntegloTM during the clinical trials were a low
count of thrombocytes, numbness in hands and feet, pain
in the bone, nausea, headache, and low blood calcium levels
(Deev et al., 2018).
A phase I/IIa clinical trial for Neovasculgen (Russian
MOH.2011), as the single product in the cardiovascular diseases
class, verified the safety of this product. In phase IIb/III trials
that enrolled 100 patients (75 in the treatment and 25 in
the control group), PWD was estimated to have increased
significantly by 110% at 6 months in the treatment group.
Moreover, PWD increased in the Neovasculgen treated group
by 167% at 1 year and 191% at 2 years after treatment. There
were no reported adverse events (Deev et al., 2015a, 2017;
NOVARTIS, 2019a). Finally, the safety and efficacy of Zolgensma
(US FDA.2019) one of the recent gene therapy products for
neurodegenerative related diseases is being evaluated in an
ongoing phase III STR1VE trial that enrolled 21 SMA pediatric
patients with biallelic mutations in the survival motor neuron
(SMN1) gene. As of the March 2019 data cutoff, remarkable
survival rates, improved rapid motor function, and the capability
to sit without support were among the most momentous results
related to the efficacy of this product. The most common adverse
events were elevated aminotransferases and vomiting (Russell
et al., 2017). Luxturna (US FDA.2017/EMA.2018), the only gene
product related to ocular diseases was assessed in a phase
III clinical trial of 31 patients with RPE65-mediated inherited
retinal dystrophy. The mean bilateral MLMT score was 1.8
light levels in the intervention group and 0.2 in the control
group. Mean FST improved by more than two log units by day
30 in the intervention group, whereas the control group had
no meaningful change. However, BCVA showed a numerical
improvement among both groups. The most common adverse
events included increased intraocular pressure, cataracts, retinal
tears, and eye inflammation (Edmonds, 2009).
Tissue-Engineered Products (TEPs)
Skin and soft tissue related disorders, orthopedic, cardiovascular
and ocular disorders are four indications for authorized TEPs.
For skin and soft tissue disorders, Apligraf (US FDA.2000),
Dermagraft (US FDA.2001), Aurix (US FDA.2007), Omnigraft
(US FDA.2016), Amniocin (Iran FDA.2017), and Cell-Amniosin
(Iran FDA.2017) are developed to treat Chronic VLU and/or
DFU. Holoderm (South Korea MFDS.2002), Epicel (US
FDA.2007), and JACE (Japan PMDA.2007) are approved for
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skin burns and finally, Kaloderm (South Korea MFDS.2005, for
burns/2010, DFU) is approved for both DFU and deep 2nd degree
burns. The safety and efficacy Apligraf compared to standard
therapy was assessed in 106 patients with neuropathic DFUs
during 12 weeks. Kaplan–Meier curves indicated that the Apligraf
treated group had a significantly faster complete wound closure
in comparison with the standard treatment; after 12 weeks, 51.5%
of patients who received Apligraf had achieved complete wound
closure compared with 26.3% in the control group. The reported
related adverse events consist of suspected wound local infection,
cellulitis, and exudate (Marston et al., 2003). A clinical study of
314 patients with chronic DFUs evaluated the safety and efficacy
of Dermagraft. The results showed a trend toward a shorter
time for complete wound healing using Dermagraft. In addition,
30.0% of Dermagraft patients achieved complete wound closure
compared with 18.3% of control patients after 12 weeks. No
specific related adverse events were reported and the incidence
of ulcer infection, cellulitis, or osteomyelitis was significantly
lower in the Dermagraft treated patients versus the control
patients (Driver et al., 2006). A clinical study of Aurix for 72
patients who suffered from non-healing DFU showed that 91%
of long-term non-healing wounds responded to treatment with a
64% reduction in volume during 15 days or less. They researchers
observed that 81.3% of Aurix treated wounds, which were less
than 7 cm2, healed completely within 6.2 weeks in comparison
with saline gel. In addition, the Kaplan–Meier time-to-healing
was significantly better in the Aurix group. No product-related
serious adverse events were reported (Driver et al., 2015). The
results of the study that evaluated the safety and efficacy of
Omnigraft in comparison to standard wound care in 307 patients
with neuropathic DFU demonstrated improved life quality,
approximately 5 weeks faster wound closure, and 19% increased
healing rate in patients treated with Omnigraft (Tego Science,
2019b). Allergic reaction was the most concern about the safety
of Omnigraft. We were unable to locate any data that pertained
to the efficacy of Holoderm; however, according to the product
brochure, abnormal cellular responses such as dyskeratosis or
parakeratosis may occur following the use of Holoderm-derived
epidermis (Food and Drug Administration, 2019i). The survival
rate of Epicel was assessed in three studies. In the first study, the
OS rate was 86.6% for overall patients and 89.3% for pediatric
patients at 3 months after the initial implantation. In the second
study, an OS rate of 88.3% in pediatric patients compared with
81.3% in the total population was reported. In the third study,
the treatment group had a 90% survival rate compared to 37.5%
for the control group. The most common adverse reactions were
infections, graft shear, blisters, drainage, sepsis, graft detachment,
and renal failure (Matsumura et al., 2016). The CEA JACE safety
and efficacy was evaluated through a 6-year multicenter clinical
trial for treatment of burns that covered more than 30% of the
TBSA. The mean CEA take rate at 4 weeks post-engraftment
was 66%, while the use of combined treatments such as artificial
dermis or a wide split-thickness auto or a patch graft significantly
elevated this rate. The most common adverse events were skin
ulcers or auto graft detachment; however, death and sepsis, which
were reported as serious adverse events during later periods, did
not appear to be related to CEA (Tego Science, 2019c). Treatment
of DFU with Kaloderm has shown that 12 weeks after treatment,
all patients in the keratinocyte-treated group and 69% of patients
in the control group experienced complete wound healing.
No adverse events were reported in relation with the wound
dressings. In terms of skin burns, the product packaging insert
for Kaloderm stated that, no adverse reaction has been reported
other than a possible occasional infection at the site, dermatitis,
exudate formation, weak edema, hypersensitivity, and pain. In
addition, Kaloderm can promote the re-epithelialization of deep
abdominal cavity burns (McGuire et al., 2011; You et al., 2012).
Gintuit (US FDA.2012) is approved for surgically created
vascular wound in the treatment of mucogingival conditions,
the results of a clinical trial with 96 patients during 6 months
follow up showed that the LCC mediated ≥ 2 mm regenerated
keratinized gingiva in 81 of 85 patients and≥ 1 mm in all patients,
while the color and texture was similar to the adjacent tissue. The
most common adverse events included sinusitis, nasopharyngitis,
respiratory tract infections, aphthous stomatitis, and the local
effects of oral surgery (Tohyama et al., 2009).
In orthopedics disorders, JACC (Japan PMDA.2012), MACI
(US FDA.2016/EMA.2013) and Spherox (EMA.2017), are used to
treat cartilage defects. JACC was studied through a multi-center
clinical trial for transplanting autologous cultured chondrocytes
in 27 patients with cartilage lesions who were evaluated at 3, 6,
12, and 24 months after the implantation surgery. Elimination
of locked knee together with decreased pain were observed
following the transplantation. Also, substantial progression of
the original knee-function scale and the clinical scores based on
the Lysholm Knee Scoring Scale, and observation of the natural
appearance in 92% of patients as indicated by arthroscopic
assessment showed restorative promotion of articular cartilage
in the knees (Saris et al., 2014). There were few adverse events,
except for two cases of graft detachment. The efficiency of
a MACI implant has been assessed and its superiority versus
microfracture treatment was evaluated in the SUMMIT clinical
trial of 144 patients. The results at week 104 revealed significant
improvement with MACI in the three KOOS subscales of
pain, SRA, and ADL when compared with the microfracture
group. Serious adverse reactions reported for MACI were
arthralgia, cartilage injury, meniscus injury, treatment failure,
and osteoarthritis (Armoiry et al., 2018). In a phase III clinical
trial, Spherox was compared with the microfracture treatment in
102 patients. The mean overall KOOS in patients treated with
Spherox increased from 56.6 ± 15.4 at baseline to 78.7 ± 18.6
after 12 months, with a further increase to 81.5 ± 17.3 after
24 months. However, the MOCART scores did not change
significantly among the two groups (Becher et al., 2017). In
a phase II clinical trial, 73 patients with cartilage defects
received transplants of three different doses (low, medium,
and high) and were subsequently followed until 36 months.
Severe adverse events included meniscus lesion with the low
dose; syncope and joint effusion with the medium dose; and
arthralgia, joint effusion, and chondropathy with the high dose
(Nordmeyer et al., 2018).
For cardiovascular diseases, CardioCel (Singapore
HAS.2014) is approved to treat ASD and VSD and Heartsheet
(Japan PMDA.2015) is developed for severe heart failure
Frontiers in Cell and Developmental Biology | www.frontiersin.org 19 December 2020 | Volume 8 | Article 547653
fcell-08-547653 December 11, 2020 Time: 21:3 # 20
Ramezankhani et al. ATMP as Emerging Therapeutics
due to ischemic heart disease. In a study, CardioCel patches
were applied on 40 patients for 2 years. While the probability
of stopping the development of the combined end point
that consisted of death, additional surgery, and a moderate
degree of aortic valve dysfunction after AVR was 92 ± 5% at
12 months, this probability reduced to 28 ± 9% at 36 months
after surgery. In this study, 23% of patients experienced an
event during follow up, which included death and additional
surgery due to stenosis, aortic valve insufficiency, and aortic
valve endocarditis (Imamura et al., 2016). Heartsheet was
evaluated in a phase II multi-center clinical trial of autologous
skeletal myoblast sheet transplantation in seven patients
with advanced heart failure compared with a control group
receiving CRT in a 1 year follow upLVRR and heart failure
symptoms improved in the treatment group and a lower rate
of cardiac death during 800 days of follow up was observed.
Common adverse events experienced by all of the patients
during the study included arrhythmia, wound complications,
hypokalemia, and post-operative fever (Rama et al., 2010).
For ocular disorder, Amniodisk (Iran FDA.2020) is approved
for Corneal ulcer, conjunctival and epithelial damage and
Holoclar (EMA.2015) is approved for severe limbal stem cell
deficiency. In a retrospective case series study, 106 patients
with corneal damage received Holoclar. As the human limbal
stem cells are recognized through p63 transcription factor
expression, the clinical outcome assessment was conducted
according to the percentage of p63-bright holoclone-forming
stem cells in culture. If this percentage was greater than 3%,
then the transplantation was considered successful. The success,
partial success, and failure rates in the transplantation process
were 76.6, 13.1, and 10.3% of the treated eyes, respectively
(European Medicines Agency, 2015). The most common adverse
reactions were blepharitis and corneal epithelium defects
(Market Research, 2020).
MARKET SIZE OF ADVANCED THERAPY
MEDICINAL PRODUCTS (ATMPs)
Price and market size are two main issues that should be
emphasized for guarantee of product survival in the market.
We have attempted to provide information of the market
size of most products introduced in this paper by preferably
accessing the appropriate company‘s available data on the
Internet. All product prices are presented in USD to be
comparable. The information regarding the market size of each
mentioned product was collected by using company’s IR book,
website, and market research websites. The disease markets were
considered based on the related CAGRs, following with the data
respecting each product.
Thus far, the area of diseases that is targeted by ATMPs
are divided into hematological disorders, skin and soft tissue
disorders, orthopedic disorders, immunological disorders,
cardiovascular diseases, neurodegenerative diseases, ocular
diseases, and cancers. The market size of each mentioned
diseases can be classified based on the industrial analysis and
CAGR. According to Mordorintelligence, the largest predicted
CAGR from 2020 till 2025 belongs to dermatology (Cancer
Therapy Market, 2020) therapeutics market (8.95%) and cancers
(Autoimmune Disease Diagnostics Market, 2020), autoimmune
disorders (Orthopedic Devices Market, 2020), orthopedic
disorders (Cardiovascular Devices Market, 2020), cardiovascular
diseases (CellTech, 2019) and the hematology (Hematology
Market, 2020) field come in the next places with the CAGRs
of 8.37, 8.3, 7.2, 6.2, and 5%, respectively. Also, predicted
CAGRs for markets of soft tissue (Soft Tissue Repair Market,
2020) repair, neurodegenerative diseases (Neurodegenerative
Disease Market, 2020), and ophthalmic disorders (Ophthalmic
Drugs Market, 2020) from 2019 till 2024 are 5.8, 5.5, and
4.6%. Therefore, beginning with dermatology therapeutics,
Fibrocell Science has announced that the sale of Azficel-T
increased approximately $0.3 million, or 63.4%, for the year
ending December 31, 2016 compared to 2015 (Fibrocell Science
Inc., 2020) Apligraf and Dermagraft have experienced strong
sales growth, with more than one million units of each one,
shipped for patient use until April 2016 (Organogenesis Inc.,
2019a) along with approximately one million patient units for
Apligraf until September 2017 (Organogenesis Inc., 2019b). Nuo
Therapeutics estimated a turn in the Aurix sales from $0.495
million in 2014, to peak sales over $50 million (Napodano, 2015).
Based on Vericel investor reports, Epicel has been administered
to approximately 100 patients in the U.S. annually, and it could
achieve $23.1 million net revenue by December 31, 2018 (Vericel
Corporation, 2019). According to the company’s IR book, the
operating margin of Tego Science Company for Kaloderm
and Holoderm products was $10.9 million in 2006, which
reached $23.4 million in 2013. Sales of Kaloderm were lower
in 2006; however, by 2013, sales of Kaloderm were significantly
higher than Holoderm (Tego Science, 2019d). As stated by
Biosolution Company’s IR book, 15% of the market in 2008
in South Korea belonged to KeraHeal in comparison with
competitive products. This amount rose to more than 70% in
2012. Regarding the market size, the number of patients in
2017 was approximately 410 with the sales percent of nearly
$9.5 million. The number of patients is expected to reach
approximately 450 in 2021 with an estimated sales of $42.6
million (Bio Solution Co Ltd., 2019). In 2017, the first year that
KeraHeal-Allo was released, it occupied 20% of the market. It
was estimated that this product would experience rapid growth
in sales during 2019. Regarding market size, in 2017 there were
approximately 203,000 persons with a sale of $7.5 million. The
numbers of patients are expected to reach 217,000 persons
in 2021 with an estimated sales of $56 million (Bio Solution
Co Ltd., 2019). The J-TEC company in 2009 has estimated
that the market size of JACE would be approximately 100 to
300 million US dollars only in Japan (Joo-sung, 2016). In the
cancer area, the Green Cross Cell company IR book estimated
that the market potential for Immuncell-LC for only the US
will be about $6 billion, with the targeted market consisting
of liver cancer, brain tumors, and pancreatic cancer (Green
Cross Cell, 2019). Also, several approved GTMP therapeutics,
Kymriah, Yescarta, Imlygic, Zalmoxis, Gendicine, and Oncorine
are indicated for oncology related diseases. Kymriah grew
strongly in Europe and US in the first quarter of 2020, with a
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net sale of $93 million (Globenewswire, 2020). Also, Yescarta’s
sale during the first quarter of 2019 was $96 million compared
to $40 million for the same period in 2018 (Business Wire,
2020). Amgen, the manufacturer of Imlygic, has not disclosed
Imlygic sales in its quarterly results presentations. However,
EvaluatePharma reported consensus analyst forecasts of $45
million and $250 million for worldwide Imlygic sales in 2016
and 2022, respectively (Imlygic, 2017). Financial reports in
2012 revealed that over 6000 patients diagnosed with various
types of solid cancers in China received Gendicin, which had
a CAGR from 2004 to 2011 of 68.3% (Kudrin, 2018). Sales of
Gendicin were $3.6 million in 2007 and $16 million in 2008.
However, the sales of Oncorine were unsatisfactory in China
(<$1.2) due to its high price in 2009 (Kudrin, 2018). Products
indicted for immunological disorders show that Alofisel is
forecasted by Evaluate Pharma that the worldwide consensus
sales will reach $529 million in 2024 (Mesoblast Limited, 2020).
In terms of the Cupistem market in South Korea, the number
of CD patients increased from approximately 15,000 in 2010
to almost 20,000 in 2014, while an increased prevalence has
also been observed (Green Cross Cell, 2019). Sales of Temcell
HS were $14.3 million in FY 2017, which showed a 124.3%
increase compared to previous fiscal years (HIYAKU, 2019). For
orthopedic disorders, in the beginning of 2019, Cartistem sold
$11.1 million and the revenues for its sale accounted for 34.4%
of the total sales in the first 6 months of 2019 (Korea Biomedical,
2020). Chondron sales for cartilage cell therapy in 2012 were
approximately $13.8 million and increased to approximately
$17.8 million in 2014 (Mksvc, 2019). In addition, Cartigrow
has been used in 140,000 knee replacement cases annually (Das,
2018). According to Orthocel, Chondrocytes-T-Ortho-ACI is
currently marketed in Australia, New Zealand, Hong Kong,
Singapore, the United States, Europe, and China. Total revenues
for its sale reached $739,100 during the 2018 fiscal year (FY).
Moreover, the revenue forecast for Chondrocytes-T-Ortho-
ACI until the FY 2028 is an estimated $340,203,044 (Hice,
2018). According to a 2018 report published in the standard
business website, Ossgrow is used in 108,000 cases of total hip
replacement in India each year (Das, 2018). TMACI, Spherox,
and JACC are other approved therapeutics for orthopedic
disorders. Vericel Company announced that MACI generated
net revenues of approximately $67.7 million in the year ending
December 31, 2018 (Vericel Corporation, 2019). CO.DON
AG, launched Spherox for distribution in European countries
in September 2017, starting from Germany. In Germany, the
market volume addressed by CO.DON AG, approximated
20,000 annual treatments. With a population of 82.2 million,
this meant that in Germany about 0.025% of the population
could receive treatment with Spherox per year. Expressed in a
conservative perspective, the potential for more than 115,000
knee-joint treatments per year was calculated in Europe.
Marketing approval of Spherox was received in May 2017 from
EMA (CODON, 2019). According to the J-TEC company’s IR
book, the sales of JACC between FY 2011–2012 were reported
to be $10.8 million compared to $371280 at its launch in 2003
(PMDA, 2011). In the field of cardiovascular diseases, according
to the FCB Pharmicell Company IR book for Cellgram-AMI,
in the South Korea the number of patients with AMI in 2015
was 87,984. The total amount of medical care costs for AMI
in the same year was $1749 million (Pharmicell Ltd., 2020).
Assessment of Neovasculogen, a product for cardiovascular
diseases in Russia, indicated that 5 million people have been
diagnosed with PAD. Also, the number of patients with CLI
annually amounts up to 145,000, of which around 25% die
(Deev et al., 2015b; NOVARTIS, 2019a). Also, the market size
for Stempeucel is approximately $1.5 billion worldwide (Lane,
2016). Moreover, the annual reports from Admedus indicated
that they achieved revenues of $6.9M million by selling their
ADAPT R©, bio-scaffold tissue technology, realted products
(including CardioCel R© Neo, VascuCel R©) in North America,
Europe, the MENA region, Asia, Australia, and New Zealand
(Cardiocel, 2017). Products based on human cord blood derived
HPCs, cover the market of hematologic disorders. Cord blood,
as stem cell sources for patients without a donor, has its own
market with more than 2000 cord blood hematopoietic stem
cell transplants performed each year (WHO, 2013). The other
approved product in this field is Zalmoxis. In 2018, Molmed
Company projected peak sales of around 100 $ million to be
achieved by 2026 for Zalmoxis (Spark Therapeutics Inc., 2019).
However, very recently MolMed decided to the withdraw the
drug’s conditional marketing authorization (CMA) after Phase
III clinical trial results showed that the drug offered no benefit
on DFS (Sharma, 2019) and stopped investing in the product.
Revenues for Zalmoxis in 2018 is estimated at approximately
$4.6 million (MolMed, 2018). In the neurological disorders, by
taking into account the production of Nuronata-r in January
2015 and based on sales for June 2015 that were approximately
$1.6 million, 2016 sales were estimated to be approximately
$4.8 million with a rapid sales growth compared to other
stem cell treatments. Also, the domestic patient sales in 2018
were expected to reach near $16.6 million which, together with
overseas patients, the final number would be approximately $37.4
million (Commercialized Stem Cell Corestem Inc., 2020). Finally,
Spark Therapeutics reported that in the year ended December
31, 2018, they recognized $64.7 million in total revenue, of
which $27.0 million was net product sales of LUXTURNA
(Spark Therapeutics Inc., 2019).
Overall, also it is worthy to note that according to the
Seoane-Vazquez et al. (2019), the treatment cost of Kymriah,
sipuleucel-T, Imlygic, and autologous cultured chondrocytes was
higher in the United States than in Europe.
CONCLUSION AND FUTURE REMARKS
Cellular therapies have attracted tremendous attention from
numerous researchers, clinicians and from industry, specifically
for incurable diseases. As it can be concluded from Tables 1–
3, most of the approved products in the recent years belong to
the CTMPs, although a decrease in the total amount of approved
products occurred in 2013 and 2014, which may be occurred due
to financial and regulatory restriction issues. For the next years,
there was an increased trend with five products approved in 2017
(Figure 3A). The year 2007 witnessed an increase in the number
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FIGURE 3 | The annual trend of approval for CTMPs, GTMPs, and TEPs worldwide. Most of the products were recently approved. (A) In terms of CTMPs, despite a
decrease in the number of approved products in 2013 and 2014, a second increased trend can be observed with five products approved in 2017. (B) For TEPs, the
year 2007 with five approved products showed an increase in the total trend; however, there was a subsequent decrease in the following years. (C) There is a
noticeable growth trend with respect to gene therapy medicinal products (GTMPs).
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of approved TEP products; however, in the next years this amount
decreased and this field has not experienced any evident growth
trend, which can be seen in two other products (Figure 3B).
GTMPs have faced an obvious progressive trend regarding the
number of approved products and this is clearly apparent from
the growth in the trend of these products, which may be due
to entrance of big pharma in this field to develop a treatment
for refractory conditions or rare diseases which do not have
an effective pharmaceutical drug. The latest approved product,
Zynteglo, is placed in this class (Figure 3C). It is expected that
with the current advances in genetic engineering, products in
this field would experience significant growth in following years.
The origin of these products is an important subject since the
use of autologous, allogeneic or xenogeneic cell sources would
have a substantial effect on the financial policies of the companies
that produce the regenerative medicine product and the related
regulatory agencies. The allogeneic based products have a
preferred advantage regarding their capability to be adapted
for scale up strategies and also catching large market through
massive export. However, as mentioned before, most members
of CTMPs and GTMPs have an autologous source, due to the
medicinal constraints in regards with immune rejection and the
extensive required safety tests for allogeneic cells, while the cells
used in tissue engineering based products with local indications,
have the higher percentage for allogeneic rather than autologous
products and have a greater market and higher sales (Kim et al.,
2019). Altogether, it seems that with release of guidelines in
different regulatory agencies the regulatory problem could be
overcome in next years and trend of allogeneic products would
raise noticeably. Market size and price are two main determinants
of a product success or failure. Glybera with a both low market
size and high price is one example of how these two factors can
affect the survival of a certain ATMP in the market. Generally,
the average prices for GTMPs are higher in comparison to
CTMPs and TEPs. ATMPs related treatments despite their great
therapeutic potential are very costly and there are challenges
regarding their reimbursement issues. The high price of ATMPs
is the result of several factors; high manufacturing costs, complex
quality control tests, expensive raw materials, requirement of
cold chains for transfer, intellectual property rules, small target
populations (in some of cases) and strict regulatory inspections
are among the most important reasons.
Due to the significant therapeutic potential of ATMPs for
serious conditions in comparison with conventional drugs, as
one of the major growth drivers for market, their market share
is anticipated to be increasing. Respecting to the new slow
shift toward personalized medicine while ATMPs are one of
the high potential players in this regard, increasing the value
of ATMPs global market size is highly expected. This idea is
strongly supported by entrance of big pharma to this field in
recent years. Moreover, the market interest has largely affected
the number of developed products. This can be seen, for instance,
in the percent of approved products for skin related application,
as they are placed in the first position of TEPs (60%) and
also CTMPs (23.5%).
Overall, the criteria regarding the efficacy of each ATMPs,
shows optimistic results and the total numbers of adverse events
are not dramatic. Cellular therapy is expected to be a promising
area used for treatment of a noticeable quantity of incurable
disorders. However, limiting factors regarding the development
and uses of ATMPs should be still overcome, including the
demand for high-technology systems for cell manufacturing and
delivery (reducing production times and costs), vectors for gene
modification availability and production, establishment of assays
to validate products potency to ultimately improve treatment
efficacy while avoiding adverse events and, last but not least
the costs of these products and their reimbursability. On the
other hand, since regenerative medicine strategies might become
a solution for treatment of still incurable diseases and due to
massive public and private investments, it is rational to claim that
this field has the potential to overcome many of the mentioned
limitations in a near future to reach a revolutionary phase in both
the pharmaceutical industry and in the clinics.
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